[go: up one dir, main page]

WO2002035991A3 - Spherical particles produced by a hot-melt extrusion/spheronization process - Google Patents

Spherical particles produced by a hot-melt extrusion/spheronization process Download PDF

Info

Publication number
WO2002035991A3
WO2002035991A3 PCT/US2001/048752 US0148752W WO0235991A3 WO 2002035991 A3 WO2002035991 A3 WO 2002035991A3 US 0148752 W US0148752 W US 0148752W WO 0235991 A3 WO0235991 A3 WO 0235991A3
Authority
WO
WIPO (PCT)
Prior art keywords
beads
hot
spheronization
pellets
extruded
Prior art date
Application number
PCT/US2001/048752
Other languages
French (fr)
Other versions
WO2002035991A2 (en
Inventor
Christopher R Young
John J Koleng
James W Mcginity
Original Assignee
Univ Texas
Christopher R Young
John J Koleng
James W Mcginity
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Christopher R Young, John J Koleng, James W Mcginity filed Critical Univ Texas
Priority to AU2002226098A priority Critical patent/AU2002226098A1/en
Publication of WO2002035991A2 publication Critical patent/WO2002035991A2/en
Publication of WO2002035991A3 publication Critical patent/WO2002035991A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00—Making granules
    • B29B9/02—Making granules by dividing preformed material
    • B29B9/06—Making granules by dividing preformed material in the form of filamentary material, e.g. combined with extrusion
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00—Making granules
    • B29B9/12—Making granules characterised by structure or composition
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/001—Combinations of extrusion moulding with other shaping operations
    • B29C48/0022—Combinations of extrusion moulding with other shaping operations combined with cutting
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/04—Particle-shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/06—Rod-shaped
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00—Making granules
    • B29B9/16—Auxiliary treatment of granules
    • B29B2009/163—Coating, i.e. applying a layer of liquid or solid material on the granule
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00—Making granules
    • B29B9/16—Auxiliary treatment of granules
    • B29B2009/166—Deforming granules to give a special form, e.g. spheroidizing, rounding

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Glanulating (AREA)

Abstract

Active agent-containing spherical pellets were successfully produced via a hot-melt extrusion/spheronization technique. The beads processed by this new technique were compared to beads produced by traditional wet-mass granulation/spheronization. The hot-melt extruded spherical pellets were manufactured by first cutting a thin, extruded rod into nearly symmetrical pellets. These pellets were then spheronized in a traditional spheronizer at an elevated temperature. Although the formulations were identical for beads processed by both techniques, beads displayed significantly different release patterns. The wet-mass granulated beads released active agent at a faster rate than the hotmelt extruded beads. Regardless of the solubility of the thermoformable composition comprising the beads, the hot-melt extruded beads exhibited greater control of active agent release than the wet-mass granulated beads. The difference in bead matrices is illustrated by scanning electron microscopy. Additionally, the beads processed by this new technique have a narrower particle size distribution. The new technique of hot-melt extrusion/spheronization can produce spherical particles without the addition of water or other solvents.
PCT/US2001/048752 2000-10-30 2001-10-29 Spherical particles produced by a hot-melt extrusion/spheronization process WO2002035991A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002226098A AU2002226098A1 (en) 2000-10-30 2001-10-29 Spherical particles produced by a hot-melt extrusion/spheronization process

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24443500P 2000-10-30 2000-10-30
US60/244,435 2000-10-30

Publications (2)

Publication Number Publication Date
WO2002035991A2 WO2002035991A2 (en) 2002-05-10
WO2002035991A3 true WO2002035991A3 (en) 2002-08-01

Family

ID=22922752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/048752 WO2002035991A2 (en) 2000-10-30 2001-10-29 Spherical particles produced by a hot-melt extrusion/spheronization process

Country Status (2)

Country Link
AU (1) AU2002226098A1 (en)
WO (1) WO2002035991A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9011963B2 (en) 2012-11-21 2015-04-21 S&P Ingredient Development, Llc Compositions of low sodium salt and methods of making and using

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
CA2598204C (en) * 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE602006019320D1 (en) 2006-01-19 2011-02-10 Dow Global Technologies Inc BIOLOGICALLY EFFECTIVE COMPOSITION WITH ETHYL CELLULOSE
US7771632B2 (en) 2006-05-15 2010-08-10 American Leistritz Extruder Corp. Continuous melt spheronization apparatus and process for the production of pharmaceutical pellets
US20070286903A1 (en) * 2006-06-13 2007-12-13 Becicka Brian T Composition and method for taste masking
CA2667890C (en) 2006-10-31 2015-01-27 Surmodics Pharmaceuticals, Inc. Spheronized polymer particles
DE102007009242A1 (en) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets with enteric-coated matix
DE102007009243A1 (en) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets with a drug matrix and a polymer coating, and a method for producing the pellets
CN101652128B (en) * 2007-03-02 2012-12-19 法纳姆公司 Sustained release compositions using wax-like materials
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
DE102007025858A1 (en) 2007-06-01 2008-12-04 Grünenthal GmbH Process for the preparation of a medicament dosage form
BRPI0906467C1 (en) 2008-01-25 2021-05-25 Gruenenthal Gmbh pharmaceutical dosage form with modified tear-resistant outer shape and controlled release
LT2273983T (en) 2008-05-09 2016-10-25 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
PE20110893A1 (en) * 2008-10-07 2012-01-18 Astrazeneca Uk Ltd PHARMACEUTICAL FORMULATION CONTAINING 4- [3- (4-CYCLOPROPANOCARBONYL-PIPERAZINE-1-CARBONYL) -4-FLUOROBENZYL] -2H-FTALAZIN-1-ONA
CN102573805A (en) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 Hot-melt extruded controlled release dosage form
TWI473628B (en) 2009-07-22 2015-02-21 Tamper-resistant dosage form for oxidation-sensitive opioids
PL2611425T3 (en) 2010-09-02 2014-09-30 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
MX2013002377A (en) 2010-09-02 2013-04-29 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt.
ES2655900T3 (en) 2011-07-29 2018-02-22 Grünenthal GmbH Tamper-proof tablet that provides immediate release of a medication
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
JP6282261B2 (en) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Unauthorized use and overdose prevention pharmaceutical dosage forms
JP6577865B2 (en) * 2012-04-25 2019-09-18 エスピーアイ ファーマ，インコーポレイテッド Process for producing crystalline microspheres and the same
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
KR20160031526A (en) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
HK1224189A1 (en) 2013-11-26 2017-08-18 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015148538A1 (en) * 2014-03-24 2015-10-01 Kashiv Pharma, Llc Method of manufacturing fine particles suitable for orally disintegrating pharmaceutical dosage forms
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (en) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Multiparticulates protected against ethanol overdose
CA2964068A1 (en) * 2014-09-19 2016-03-24 Board Of Regents, The University Of Texas System Methods of preparing extrudates
MX2017013637A (en) 2015-04-24 2018-03-08 Gruenenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction.
WO2017005622A1 (en) * 2015-07-03 2017-01-12 Dsm Ip Assets B.V. Novel extrudates
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3681686A1 (en) * 2017-09-12 2020-07-22 Dressler Group GmbH & Co. KG Method and device for thermal rounding or spheronisation of powdered plastic particles
EP3459527B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
CN109925290B (en) * 2017-12-18 2021-03-16 广州白云山明兴制药有限公司 Theophylline sustained release tablet and preparation process thereof
JP6609726B1 (en) * 2018-02-07 2019-11-20 株式会社ダイセル Cellulose acetate particles, cosmetic composition and method for producing cellulose acetate particles
CN110405977B (en) * 2019-07-19 2021-10-12 合肥智慧殿机械设计有限公司 Lateral feeding granulator for arc cutting of elastomer prism surface of film dry material package clamp
WO2024263880A1 (en) * 2023-06-22 2024-12-26 Koppers Performance Chemicals, Inc. Methods of manufacture of biocidal compositions, articles for storing biocidal compositions, wood preservative solutions, and wood products produced therefrom

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007859A1 (en) * 1991-10-23 1993-04-29 Warner-Lambert Company Novel pharmaceutical pellets and process for their production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007859A1 (en) * 1991-10-23 1993-04-29 Warner-Lambert Company Novel pharmaceutical pellets and process for their production

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9011963B2 (en) 2012-11-21 2015-04-21 S&P Ingredient Development, Llc Compositions of low sodium salt and methods of making and using

Also Published As

Publication number Publication date
AU2002226098A1 (en) 2002-05-15
WO2002035991A2 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
WO2002035991A3 (en) Spherical particles produced by a hot-melt extrusion/spheronization process
CA2127352C (en) Pharmaceutical preparation in the form of an effervescent and/or disintegrating tablet or an instant granulate, and process for producing it
JP2697754B2 (en) Pharmaceutical pancreatin micropellet particles, method for preparing the particles, gastric juice-resistant coated pancreatin micropellets for pharmaceutical, and method for manufacturing the micropellets
AU659529B2 (en) Pharmaceutical compositions containing nifedipine and process for the preparation thereof
BR0012250A (en) Manufacturing process of masked taste coated granules, and immediate release of the active ingredient, coated granule, fast dissolving multiparticulate tablet and fast hydrodispersible tablet
JPS5826315B2 (en) Enzyme granules and manufacturing method
EP0508653B1 (en) Sustained-release pharmaceutical preparation and process for preparing the same
JPH06292825A (en) Stabilized active powdery component, composition containing said component, method of obtaining the same and application thereof
JP2009502487A5 (en)
EP1233756A1 (en) Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR900009059A (en) Granules for Multiparticulate Release Control Oral Compositions
IL160103A0 (en) Aqueous dispersion comprising stable nanoparticles of a water-insoluble active substance and an excipient like middle chain triglycerides (mct)
ATE234116T1 (en) AGGLOMERATES OR SPHERICAL PARTICLES OF POLYVALENT METAL ALGINATES, CONTROLLED RELEASE COMPOSITIONS BONDED TO THE AGGLOMERATES CONTAINING POORLY SOLUBLE DRUGS, AND METHODS FOR THE PRODUCTION THEREOF
AU765765B2 (en) Particles coated with granulated crystalline ibuprofen
BR9912846B1 (en) process for manufacturing a controlled release tablet.
ATE292958T1 (en) INSTANT GRANULES AND METHOD FOR THE PRODUCTION THEREOF
IS6511A (en) Pharmaceutical preparations containing sugar fatty acid esters to control the release of active ingredients
WO2016005994A2 (en) Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires
DE69910188T2 (en) MEDICINE CONTAINING CARVEDILOL
JP2007517864A (en) Cefuroxime axetil granules and method for producing the same
JP2002527578A (en) Method for producing microporous granular material and detergent composition
CN101874784A (en) Precipitation and crystallization drug sustained and controlled release microspheres and preparation method thereof
Ibrahim et al. Dissolution characteristics of interactive powder mixtures. Part one: Effect of solubility and particle size of excipients
JP5042447B2 (en) Mixed preparation
JPS6037983A (en) Production of granulated enzyme

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP